David M. Swoboda

1 month ago | onclive.com | Gustavo Rivero |David M. Swoboda

FeatureArticleFebruary 28, 2025Oncology Live®Vol. 26 No. 2Volume26 Issue 2Author(s):, Revumenib, a menin inhibitor, is approved for relapsed/refractory leukemias with KMT2A translocations, showing significant efficacy in clinical trials. The AUGMENT-101 trial demonstrated a 63.2% overall response rate, prompting further investigation of revumenib in combination therapies.

Jan 15, 2025 | targetedonc.com | Guillermo Garcia-Manero |David M. Swoboda

January 15, 2025By Panelists discuss key learnings from recent studies on lower-risk myelodysplastic syndrome (LR-MDS) treatment, identify remaining knowledge gaps, and offer final takeaways, including their thoughts on the role of luspatercept in the evolving LR-MDS treatment landscape, clinical pearls for community oncologists, and major unanswered questions that could improve outcomes for LR-MDS and anemia management in the future.

Jan 15, 2025 | targetedonc.com | Guillermo Garcia-Manero |David M. Swoboda

January 15, 2025By Panelists discuss second-line (2L) treatment strategies for lower-risk myelodysplastic syndrome (LR-MDS), focusing on how to choose a 2L treatment for patients refractory to first-line options, and provide an overview of recent updates from the IMerge trial (Santini et al, EHA 2024; Zeidan et al, JCO 2024), while considering the role of imetelstat in treatment sequencing according to NCCN Guidelines MDS-5. Please give an overview of 2L treatment strategies.

Jan 8, 2025 | targetedonc.com | Guillermo Garcia-Manero |David M. Swoboda

January 8, 2025By Panelists discuss real-world evidence on dose escalation of luspatercept in lower-risk myelodysplastic syndrome (LR-MDS) (Patel et al, EHA 2024), highlighting its clinical benefits in improving patient outcomes, and share insights from the MAXILUS trial (Della Porta et al, EHA 2024), considering how this dosing strategy could influence clinical practice and enhance patient care.

Jan 8, 2025 | targetedonc.com | Guillermo Garcia-Manero |David M. Swoboda

Sandra M. Swain, MD, FACP, FASCO, discusses the potential role for HER2-directed TKIs for the treatment of patients with early-stage HER2+ breast cancer and shares insights about emerging data that could impact the future treatment landscape.